Linked Life Data

367906

Source:http://linkedlifedata.com/resource/pubmed/id/367906

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2-3
pubmed:dateCreated
1979-4-28
pubmed:abstractText
30 asthenozoospermic subfertile men were treated parenterally for 30 months with kallikrein. 20 men showed a significant increase in sperm motility, 66% (responders), while the other 10 men, 34% (non-responders), did not respond to this treatment. A striking decrease in sperm concentration (by 32%) was found in most patients. No latent period was found following kallikrein treatment. Thus, semen quality did not differ if examined immediately following the cessation of treatment or a few weeks afterwards. A poor pregnancy rate was recorded, i.e. 20% among the responders and 10% among the non-responders. In conclusion, kallikrein is a useful drug in the treatment of asthenozoospermia only when the sperm concentration is not decreased below the optimal value.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0378-7346
pubmed:author
pubmed:issnType
Print
pubmed:volume
9
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
132-8
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
1978
pubmed:articleTitle
Evaluation of semen quality following kallikrein treatment.
pubmed:publicationType
Journal Article, Clinical Trial